TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02269969
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00125255
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Study: NCT00125255
Drug: Placebo Peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Study: NCT02072668
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
Study: NCT00429026
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV Daily for 2 Days
Study: NCT00974792
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00974792
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00974792
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00974792
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00628420
Drug: ACP-104
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
Study: NCT00628420
Drug: ACP-104
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
Study: NCT00628420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
Study: NCT01457703
Drug: Recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used to stimulate ovarian function in women.
Study: NCT00632229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Study: NCT03000608
Drug: SAN021 Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT03000608
Drug: SAN021 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT02743052
Drug: Anticoagulation treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
Study: NCT04964180
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
Study: NCT01817153
Drug: hydrocortison hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01817153
Drug: placebo followed by hydrocortisone hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01694849
Drug: GFT505 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01694849
Drug: GFT505 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01694849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00766870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per oral doses, twice daily as capsules during 10 weeks
Study: NCT01770080
Drug: Euminz®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 5 time topical use of study drug.
Study: NCT01770080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 5 time topical use of study drug.
Study: NCT02858622
Drug: perfalgan
Normalized name: PERFALGAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous paracetamol
Study: NCT02858622
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01723982
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01258803
Drug: Placebo MDI without spacer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study: NCT01263366
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
Study: NCT03817658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months.
Study: NCT01678287
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01678287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00779142
Drug: Methotrexate intravenous 25mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
Study: NCT01348074
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
Study: NCT02233686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03955146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
Study: NCT00630838
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.
Study: NCT00630838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Study: NCT04456816
Drug: 100 mg AP1189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AP1189 tablet
Study: NCT04456816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT01074060
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02045940
Drug: GSK2881078
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
Study: NCT02045940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
Study: NCT03487562
Drug: DWP14012 Bmg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 Bmg
Study: NCT03487562
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg
Study: NCT03029572
Drug: Diet supplementation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutriment supplementation therapy
Study: NCT03457701
Drug: Ferrous sulfate containing the stable iron isotope (57Fe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
Study: NCT03457701
Drug: Ferrous sulfate containing the stable iron isotope (58Fe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
Study: NCT04017546
Drug: CYC065
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00794716
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
Study: NCT02931357
Drug: Calgel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
Study: NCT03089229
Drug: HAT01H Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT03089229
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT03127072
Drug: chemotherapy ± target therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy ± target therapy
Study: NCT04600115
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
Study: NCT00719511
Drug: Purified allergen integrated in a Patch system
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous application of a patch
Study: NCT04192292
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
Study: NCT01648517
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
Study: NCT01648517
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
Study: NCT00911170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single subcutaneous injection using a pre-filled syringe.
Study: NCT00911170
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.
Study: NCT06593743
Drug: Intraanal NRL001 Gel 2 strengths
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single application of 3.0% or 1.0% Gel
Study: NCT06593743
Drug: NRL001: 10mg suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 10mg suppository applied to rectum.
Study: NCT02581657
Drug: PE0139 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE0139 Injection
Study: NCT02530034
Drug: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00663208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
Study: NCT00318032
Drug: multi-factorial intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02496715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler
Study: NCT02876211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 capsules/three times per week
Study: NCT03840421
Drug: cisplatin and fluorouracil
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study: NCT00755560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 15 days
Study: NCT01069692
Drug: SBR759A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759A 6g daily
Study: NCT01069692
Drug: SBR759A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator 0g daily
Study: NCT01069692
Drug: SBR759A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759A 3g daily
Study: NCT01069692
Drug: SBR759A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9g daily
Study: NCT01069692
Drug: SBR759A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12g daily
Study: NCT01266967
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Study: NCT02493712
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 capsules of IBD98-M, twice a day
Study: NCT02493712
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of IBD98-M
Study: NCT02493712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00777504
Drug: stop oral angiogenesis inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: see under 'study arms'
Study: NCT04437654
Drug: Anticoagulation group(Apixaban group)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study: NCT03764241
Drug: Vitamin K Antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study: NCT02405078
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given standard salvage chemotherapy
Study: NCT01184092
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
Study: NCT01184092
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
Study: NCT06176079
Drug: Hyperpolarized (HP) 13C
Normalized name: (13C)urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
Study: NCT06176079
Drug: Hyperpolarized 13C-Urea
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intravenously (IV)
Study: NCT02318706
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02318706
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01347112
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill twice daily for 12 weeks
Study: NCT03706755
Drug: Norepinephrine: 1mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Study: NCT03706755
Drug: Norepinephrine 0,5mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Study: NCT01345162
Drug: Ketorolac postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10mg 1cp x 3/die
Study: NCT01345162
Drug: postoperative Patrol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
Study: NCT01345162
Drug: intraoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg iv
Study: NCT01345162
Drug: intraoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
Study: NCT01601236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
Study: NCT04950647
Drug: Nitroketazine Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
Study: NCT04950647
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
Study: NCT03373422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT02798627
Drug: NS2359
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
Study: NCT02798627
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills identical in appearance to the NS2359 will be provided
Study: NCT03098875
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia using remifentanil as an analgesic.
Study: NCT03217604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo
Study: NCT02671708
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT01969136
Drug: Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01969136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03137381
Drug: CTP-543 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as tablets.
Study: NCT04589741
Drug: CAV/IE alternate chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Study: NCT03779295
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The entire face (both halves) will receive clindamycin.
Study: NCT02190994
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: used intravenously